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ABSTRACT
Aims-SIRT1 exerts potent activity against cellular senescence and vascular 
ageing. By decreasing LKB1 protein levels, it promotes the survival and regeneration 
of endothelial cells. The present study aims to investigate the molecular mechanisms 
underlying SIRT1-mediated LKB1 degradation for the prevention of vascular ageing.
Methods and Results-Co-immunoprecipitation assay demonstrated that SIRT1, 
via its amino-terminus, binds to the DOC domain of HERC2 [HECT and RLD domain 
containing E3 ubiquitin protein ligase 2], which then ubiquitinates LKB1 in the nuclear 
compartment of endothelial cells. Site-directed mutagenesis revealed that acetylation 
at lysine (K) 64 of LKB1 triggers the formation of SIRT1/HERC2/LKB1 protein complex 
and subsequent proteasomal degradation. In vitro cellular studies suggested that 
accumulation of acetylated LKB1 in the nucleus leads to endothelial activation, in 
turn stimulating the proliferation of vascular smooth muscle cells and the production 
of extracellular matrix proteins. Chromatin immunoprecipitation quantitative PCR 
confirmed that acetylated LKB1 interacts with and activates TGFβ1 promoter, which 
is inhibited by SIRT1. Knocking down either SIRT1 or HERC2 results in an increased 
association of LKB1 with the positive regulatory elements of TGFβ1 promoter. In mice 
without endothelial nitric oxide synthase, selective overexpression of human SIRT1 
in endothelium prevents hypertension and age-related adverse arterial remodeling. 
Lentiviral-mediated knockdown of HERC2 abolishes the beneficial effects of endothelial 
SIRT1 on both arterial remodeling and arterial blood pressure control. 
Conclusion-By downregulating acetylated LKB1 protein via HERC2, SIRT1 fine-
tunes the crosstalk between endothelial and vascular smooth muscle cells to prevent 
adverse arterial remodeling and maintain vascular homeostasis.  
INTRODUCTION
Aged arteries are characterized by augmented 
stiffness and reduced compliance, leading to the 
elevation of arterial blood pressure and increased risk of 
cardiovascular diseases [1]. Arteries become stiffer with 
age due to structural remodeling [2]. In human carotid 
arteries, the intima-media thickness increases nearly 
linearly with age, as a result of the proliferation/migration 
of smooth muscle cell and structural/compositional 
changes in elastin/collagen fibers [3]. Arterial stiffness is 
a strong predictor of cardiovascular events and all-cause 
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mortality [4].  
Crosstalk between the endothelial and surrounding 
vascular smooth muscle cells control the process of arterial 
remodeling [5]. In aged arteries, impaired endothelial 
function promotes non-compensated and pathological 
remodeling of the blood vessel wall [6]. With reduced 
blood flow, atherosclerotic lesions, angioplasty or grafting, 
arterial remodeling is also triggered by local endothelial 
dysfunction [7]. Reversing or stabilizing arterial 
remodeling represents a promising approach for both 
prevention and treatment of cardiovascular complications 
caused by hypertension and atherosclerosis [8].
SIRT1 is a NAD-dependent protein deacetylase and 
the most important member of the anti-ageing protein 
family of sirtuins [9]. SIRT1 in endothelial cells plays 
a unique vasoprotective role by regulating a number of 
proteins including endothelial NO synthase (eNOS), liver 
kinase B1 (LKB1), p53, NFκB, forkhead box protein O1 
(FOXO1) and Notch intracellular domain (NICD) [10-14]. 
Increased SIRT1 activity prevents endothelial senescence 
[10, 12], promotes endothelial angiogenesis and migration 
[15], enhances endothelium-dependent vasodilatation 
[16], and suppresses vascular inflammation and foam 
cell formation [17]. These beneficial effects contribute 
in conjunction to the anti-vascular ageing properties of 
SIRT1. 
In humans, variations of the SIRT1 gene are 
associated with increased intima-media thickness of the 
carotid arteries [18]. In mice, neointima formation is 
accompanied by a progressive down-regulation of SIRT1 
[19]. In cultured endothelial cells, laminar flow increases 
whereas oscillating flow decreases the expression and 
activity of SIRT1 [20, 21]. Despite this information, it 
is unclear whether or not endothelial SIRT1 modulates 
arterial remodeling, and if so, by what mechanism(s). 
The serine/threonine protein kinase LKB1 
plays an important role in endothelial senescence and 
vasculogenesis/arteriogenesis [12, 22, 23]. SIRT1 down-
regulates the protein levels of LKB1 in endothelial 
cells by promoting its ubiquitination and proteasome-
mediated degradation [10-12, 24]. The present study 
tested the hypothesis that endothelial SIRT1 prevents 
non-compensated and/or pathological arterial remodeling 
and vascular ageing by regulating the protein stability of 
LKB1.
RESULTS
LKB1 accumulation in endothelial cells promotes 
the proliferation of vascular smooth muscle cells
SIRT1 prevents endothelial senescence by enhancing 
the protein ubiquitination and proteasomal degradation 
of LKB1 [10, 12, 25]. HERC2, a giant scaffold protein 
and E3 ubiquitin ligase, is one of the binding partners of 
SIRT1 [26]. The present results showed that HERC2, but 
not other members of the HERC family, interacted with 
SIRT1 (Figure 1A). In endothelial cells derived from 
murine and porcine arteries, mRNA levels of HERC2 
were significantly higher than those of other HERC 
family members (Supplementary Figure 1). Knocking 
down HERC2 significantly increased LKB1 protein 
levels in primary porcine aortic endothelial cells (PAEC), 
but not in porcine coronary artery smooth muscle cells 
(PCASMC) (Figure 1B). The portion of senescent cells 
was significantly augmented to ~45% in PAEC transfected 
with specific HERC2 RNAi or expression vector encoding 
LKB1 (Figure 1C).
Quantitative real-time PCR (QPCR) analysis 
demonstrated that both down-regulation of HERC2 and 
up-regulation of LKB1 significantly enhanced the mRNA 
expression levels of transforming growth factor beta-
1 (TGFβ1; a morphogen and growth stimulator during 
vasculogenesis/arteriogenesis [27]) (Figure 1D, top 
panels). Accordingly, the conditioned media collected 
from PAEC with decreased HERC2 or increased LKB1 
expression significantly stimulated the proliferation of 
PCASMC (Figure 1D, bottom panels). 
Protein complexes containing HERC2, SIRT1 and 
LKB1 were detected mainly in the nuclear but not the 
cytosolic compartment of PAEC (Figure 2A), and human 
umbilical vein endothelial cells (HUVEC) (Supplementary 
Figure 2A and 2B). Knocking down either HERC2 or 
SIRT1 significantly enhanced the accumulation of LKB1 
in the nuclear but not the cytosolic fractions of PAEC 
(Figure 2B). Nuclear LKB1 was heavily ubiquitinated and 
significantly up-regulated by the treatment with MG132, a 
specific proteasome inhibitor (Figure 2C). 
Next, the association of LKB1 with human TGFβ1 
promoter was evaluated in HUVEC by chromatin 
immunoprecipitation quantitative PCR (ChIP-qPCR). 
The region between 453 and 323 base pairs (bp) upstream 
of the transcriptional start site and a second region from 
+1 to +271 bp contain positive regulatory activities for 
cell-specific expression as well as auto-induction by TGFβ 
[28]. LKB1 bound to both positive regulatory regions of 
TGFβ1 promoter, referred to as PRR1 and PRR2, but not 
to the negative regulatory sequences (NRR1 and NRR2) 
(Figure 2D, left panel). SIRT1 also associated with PRR1 
and PRR2 of TGFβ1 promoter in HUVEC (Supplementary 
Figure 2C). Knocking down either HERC2 or SIRT1 
significantly enhanced the binding of LKB1 to the positive 
transcriptional regulatory regions of TGFβ1 promoter 
(Figure 2D, middle and right panels). 
The above results demonstrate that accumulation 
of LKB1 in endothelial cells promotes the proliferation 
of vascular smooth muscle cells. SIRT1 and HERC2 
decrease LKB1 protein levels selectively in the nuclear 
compartment of endothelial cells. 
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Figure 1: Knocking down HERC2 or overexpressing LKB1 in endothelial cells promotes the proliferation of vascular 
smooth muscle cells. A. Co-immunoprecipitation was performed in primary porcine aortic endothelial cells (PAEC) using antibodies 
against SIRT1. The protein presence of HERC1, HERC2 and HERC3 in the immunoprecipitates were detected by Western blotting using 
their specific antibodies. B. PAEC and porcine coronary artery smooth muscle cells (PCASMC) were transfected with control or HERC2 
RNAi. Seventy-two hours after transfection, the protein amount of LKB1 and HERC2 was measured by Western blotting. The results are 
presented by fold changes against the PAEC control RNAi group. C. SA-β-gal staining was performed in PAEC transfected with control 
RNAi, HERC2 RNAi, pcDNA or LKB1-WT-3FLAG. The positively stained cells were counted manually and the results are expressed as 
percentage of the total number of cells for comparison. D. QPCR was performed to measure the expression of TGFβ1 in PAEC treated as 
above (top panels). Results are presented as fold changes against the corresponding treatment control. In addition, the conditioned culture 
media were collected for proliferation assays (bottom panels). After high speed centrifugation to remove cellular debris, the supernatant 
was diluted [1:2 ratio] with fresh culture medium and used for incubation with PCASMC for another 36 hours. At the end of treatment, 
crystal violet staining was performed to compare degrees of cell proliferation. Results are presented as percentage changes. *, P < 0.05 vs 
corresponding control groups (n = 3-6). 
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SIRT1 and HERC2 act synergistically to prevent 
the nuclear accumulation of LKB1 in endothelial 
cells 
Knocking down HERC2 did not inhibit the 
interactions between SIRT1 and LKB1, but reduced 
the amount of ubiquitin conjugated to LKB1 (Figure 3, 
left panels of A and B). By contrast, down-regulation of 
SIRT1 abolished the interactions between HERC2 and 
LKB1 as well as the ubiquitination of LKB1 (Figure 3, 
right panels of A and B). In cells overexpressing SIRT1, 
the protein interactions between endogenous HERC2 
and LKB1 were enhanced significantly (Figure 3C). 
However, the expression and ubiquitination of SIRT1 
were not significantly altered by down-regulation of 
HERC2, and the protein levels of HERC2 remained stable 
after transient overexpression of either SIRT1 or LKB1 
(Supplementary Figure 3). An in vitro ubiquitination assay 
was performed using immunoprecipitated HERC2, with 
His-tagged recombinant LKB1 or SIRT1 as the substrates. 
In the presence of E1 (UBA1) and E2 (UbcH5a or Ubc13), 
HERC2 was able to ubiquitinate LKB1 but not SIRT1 
(Figure 3D). 
HERC2 protein consists of three RCC-like domains 
(RLD1-3), a zinc finger domain (ZZ), an anaphase-
promoting complex subunit 10/DOC domain, and a 
carboxy-terminal HECT domain (Figure 4A). Next, 
mammalian expression vectors were constructed to 
produce the FLAG-tagged DOC (HERC2-DOC) and 
RCC2 (HERC2-RCC2) domains, which are uniquely 
present in HERC2 but not the other HERC family 
members [29], as well as the FLAG-tagged HECT domain 
(HERC2-HECT) that possesses E3 ubiquitin-ligase 
activity and shares high sequence homology with HERC3, 
HERC4, HERC5 and HERC6 [30, 31]. Expression of the 
three domains of HERC2 was confirmed in transiently 
transfected HEK293 cells by Western blotting using 
antibodies recognizing the FLAG epitope or the carboxyl-
terminus of HERC2 (Figure 4B). 
Next, co-immunoprecipitations were performed 
to elucidate domain-domain interactions. Endogenous 
SIRT1 was immunoprecipitated (with anti-FLAG 
antibodies) from cells overexpressing HERC2-DOC or 
HERC2-RCC2, but not HERC2-HECT domains (Figure 
4C, left panel). LKB1 could not be detected in any of the 
immunocomplexes by Western blotting using anti-LKB1 
and secondary antibodies recognizing both heavy and 
light chains or only the F(ab) fragment of IgG (Figure 
4C, middle and right panels). When using anti-SIRT1 
antibodies for co-immunoprecipitation, HERC2-DOC 
and HERC2-RCC2, but not HERC2-HECT, were present 
in the immunocomplexes (Figure 4D, left panel). When 
using anti-LKB1 antibodies for co-immunoprecipitation, 
HERC2-DOC and HERC2-RCC2 were barely detected in 
the immunocomplexes by anti-FLAG antibodies (Figure 
4D, middle panel). The weak interactions between these 
two domains and LKB1 were abolished after knocking 
down SIRT1 (Figure 4D, middle panel). In cells 
overexpressing HERC2-HECT with or without a FLAG-
tag, co-immunoprecipitation performed with anti-LKB1 
antibodies could not precipitate any HERC2 subdomains 
(Figure 4D, right panel).   
In line with the above findings, overexpression of 
HERC2-HECT did not reduce the amount of LKB1 protein 
and had no effects on the ubiquitination levels of LKB1 
or SIRT1 (Supplementary Figure 4). In vitro pull-down 
experiments showed that the amino-terminus (HERC2-
NH2) and the CPH domain (HERC2-CPH) of HERC2 did 
not bind to SIRT1 or LKB1 (Supplementary Figure 5A), 
whereas the p53 protein was precipitated by HERC2-CPH 
[32]. Compared to full-length SIRT1, a truncated form 
of SIRT1 lacking the amino-terminal 105 residues could 
not downregulate LKB1, and lost the binding capacity to 
HERC2 (Supplementary Figure 5B and 5C). 
The above findings indicate that SIRT1 via its 
amino-terminus binds to the HERC2-DOC domain 
and brings HERC2 in close proximity to LKB1 
(Supplementary Figure 5D). The formation of the SIRT1/
HERC2/LKB1 protein complex triggers subsequent 
ubiquitination and proteasomal degradation of LKB1 in 
the nuclear compartment of endothelial cells. 
Acetylation of LKB1 at K64 facilitates the 
formation of protein complexes with SIRT1 and 
HERC2  
In PAEC, proteins containing acetylated-lysine 
residues mainly accumulated in the nuclei (Figure 5A, 
top panels). Likewise, the majority of LKB1 within the 
nuclear compartment was acetylated (Figure 5A, bottom 
panels). To address whether or not acetylation plays a 
role in the ubiquitination and degradation of LKB1, a 
series of single, double or triple mutants with lysine (K) 
residues 48, 62, 64 and/or 329 replaced by glutamine 
(Q, as a mimic of acetyl-lysine) or arginine (R, as a 
mimic of non-acetylated lysine) were examined (data 
not shown). K64Q significantly enhanced the binding of 
LKB1 to SIRT1/HERC2, whereas the K64R mutation 
attenuated the interaction between LKB1 and SIRT1, 
and the subsequent association with HERC2 (Figure 
5B). The increased interaction between K64Q and SIRT1 
was further confirmed by an in vitro pull-down assay 
(Supplementary Figure 6A). Compared to WT-LKB1 
and K64Q, K64R exhibited an enhanced interaction with 
STRADα (Supplementary Figure 6B), a pseudokinase that 
inhibits LKB1 nuclear importation [33]. As a result, K64R 
protein levels were significantly decreased in the nucleus 
of endothelial cells (Supplementary Figure 6C).     
When compared to wild type (WT)-LKB1 and 
K64R, K64Q was heavily ubiquitinated in the nuclear 
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Figure 2: SIRT1 and HERC2 downregulates LKB1 in the nuclear compartments of endothelial cells. A. Total cell 
lysates or subcellular (cytosol and nuclear) fractions were prepared from PAEC treated with MG132 (10 μM, six hours) and subjected 
to co-immunoprecipitation (Co-IP) using antibodies against LKB1 or SIRT1. The amounts of immunoprecipitated HERC2, SIRT1 and 
LKB1 were detected by Western blotting. GAPDH and histone H3 were probed as markers indicating the purity of the cytosol and nuclear 
fractions, respectively. B. PAEC were transfected with control, SIRT1 or HERC2 RNAi. Seventy-two hours after transfection, nuclear and 
cytosol fractions were obtained for Western blotting to measure the protein amount of LKB1. Down-regulation of SIRT1 or HERC2 was 
confirmed in total cell lysates. C. PAEC were transfected (left panel) or not (middle and right panels) with an expression vector encoding 
the HA-tagged ubiquitin (HA-Ub). After treatment with MG132 (10 μM, six hours), cells were collected for immunoprecipitation and 
Western blotting to probe ubiquitinated LKB1 using anti-HA antibodies (left panel). The protein amount of LKB1 in nuclear and cytosol 
fractions was measured by Western blotting and are presented as fold changes (middle and right panels). D. The binding of LKB1 to TGFβ1 
promoter was evaluated by ChIP-qPCR in human umbilical vein endothelial cells (HUVEC) using primers listed in Supplementary Table 3. 
After confirming the association of LKB1 to two of the tested regions (left panel), ChIP-qPCR was performed in HUVEC transfected with 
control, HERC2 or SIRT1 RNAi to compare the association of LKB1 with PRR1 (-453 to -323, middle panel) and PRR2 (+1 to +271, right 
panel). Bar charts represent the quantitative results by QPCR analysis after normalization against the input DNA. Representative agarose 
gel images are shown at the bottom. *, P < 0.05 vs corresponding control groups (n = 3-6). 
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compartment of PAEC (Figure 5C, top panel). In the 
presence of a protein synthesis inhibitor, cycloheximide, 
K64Q exhibited significantly decreased protein stability, 
whereas K64R remained stable (Figure 5C, bottom panel). 
Knocking down either SIRT1 or HERC2 significantly 
increased K64Q protein levels in the nuclear but not the 
cytosolic fractions of PAEC (Figure 5D). Consistently, 
overexpression of SIRT1 primarily reduced the nuclear 
content of K64Q (Supplementary Figure 7). 
Compared to WT-LKB1, overexpression of 
K64Q for 48 hours reduced the total number of PAEC 
by approximately 32%, due largely to the induction 
of apoptosis (Supplementary Figure 8). Accordingly, 
the percentage staining of senescence-associated 
β-galactosidase (SA-β-gal) in PAEC overexpressing 
K64Q was only ~25% (Figure 6A). Conditioned media 
from PAEC overexpressing K64Q stimulated PCASMC 
proliferation to a significantly higher level than those 
collected from cells overexpressing WT-LKB1 or K64R 
(Figure 6B). Moreover, the amount of K64Q associated 
with TGFβ1 promoter was significantly increased when 
compared to WT-LKB1 and K64R (Figure 6C). In addition 
to TGFβ1, overexpression of K64Q significantly enhanced 
the mRNA expressions of other genes involved in 
endothelial activation and extracellular matrix deposition 
(Figure 6D).   
Figure 3: HERC2 mediates the ubiquitination of LKB1 in endothelial cells. A. Co-immunoprecipitation was performed 
in PAEC transfected with control, HERC2 or SIRT1 RNAi using antibodies against LKB1. The protein amounts of HERC2 and SIRT1 
were measured in the immunoprecipitates by Western blotting using specific antibodies. B. PAEC were transfected with HA-Ub together 
with either control, HERC2 or SIRT1 RNAi. After exposure to MG132 (10 μM, six hours), cells were lysed in a buffer containing 1% 
SDS and heated for ten minutes at 95°C. Immunoprecipitation was performed with antibody against LKB1. The amount of HA-tagged 
polyubiquitin in LKB1 was determined by Western blotting using anti-HA antibodies. C. PAEC were transiently transfected with pcDNA 
or hSIRT1-3FLAG for co-immunoprecipitation using antibodies against LKB1. Western blotting was performed to detect HERC2 in the 
immunocomplexes. The ratio between immunoprecipitated HERC2 and LKB1 was calculated for comparison. *, P < 0.05 vs pcDNA (n 
= 3). D. An in vitro ubiqutination assay was performed as described in Methods. The reaction mixture was subjected to Western blotting 
for detecting the ubiquitinated LKB1 (left) or SIRT1 (right) with antibodies against LKB1 or SIRT1, respectively. When compared to the 
control sample, ubiquitinated LKB1 appeared as a higher molecular weight species. 
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Figure 4: SIRT1 binds to HERC2-DOC domain to facilitate the interactions between HERC2 and LKB1. A. HERC2 is a 
large protein containing three RCC-like domains (RLD 1-3), a zinc finger domain (ZZ), an anaphase-promoting complex homolog domain 
(DOC) and a carboxy-terminal HECT domain [55]. Two prokaryotic expressing vectors producing HERC2-NH2 (amino acid 1-199) and 
HERC2-CPH (amino acid 2547-2640) fragments (Supplementary Figure 5), and three mammalian expressing vectors encoding HERC2-
DOC (amino acid 2765-2910), HERC2-RCC2 (amino acid 2786-3642) and HERC2-HECT (amino acid 4419-4834) domains were used for 
domain-interaction studies. B. HEK293 cells were transiently transfected with pcDNA, DOC-3FLAG, RCC2-3FLAG or HECT-3FLAG. 
The expressions of HERC2-DOC, HERC2-RCC2 and HERC2-HECT were confirmed by Western blotting using anti-FLAG (top panel) or 
anti-HERC2 (bottom panel) antibodies, the latter recognizing the carboxyl terminus of HERC2. C. Co-immunoprecipitation was performed 
in lysates from the transfected cells using anti-FLAG antibodies. The eluted immunocomplexes were subjected to Western blotting to detect 
the presence of SIRT1 (left panel) or LKB1 (middle and right panels) using their specific antibodies. Note that LKB1 was absent after probing 
with secondary antibodies recognizing both heavy and light chains (middle panel) or only the F(ab) fragment of IgG (right panel). D. Co-
immunoprecipitation was performed using anti-SIRT1 antibodies. The presence of HERC2 sub-domains was detected by Western blotting 
using an anti-FLAG antibody (left panel). Interactions between LKB1 and HERC2 domains were investigated by co-immunoprecipitation 
in cells overexpressing HERC2-DOC or HERC2-RCC2, with co-transfection of control or SIRT1 RNAi (middle panel). In addition, cells 
overexpressing HERC2-HECT in either FLAG-tagged or non-tagged form were subjected to co-immunoprecipitation using anti-LKB1 
antibodies. The presence of HERC2 sub-domains was examined by Western blotting using anti-HERC2 antibodies (right panel). The 
arrows indicate non-specific signals from IgG heavy chain.
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Figure 5: Acetylation of LKB1 at lysine 64 facilitates its interactions with SIRT1/HERC2 and protein degradation in 
the nuclear compartment of endothelial cells. A. PAEC were subjected to immunofluorescence staining with antibodies against 
acetylated-lysine (top panel). Magnification, 400x. LKB1 was immunoprecipitated from nuclear or cytosol fractions of PAEC. The amount of 
acetylated LKB1 was measured by Western blotting using antibodies against acetylated-lysine (bottom panel). The ratio between acetylated 
and immunoprecipitated (ip) LKB1 was calculated for comparison. *, P < 0.05 vs nuclear fractions (n = 3). B. Co-immunoprecipitation (Co-
IP) was performed in PAEC transiently overexpressing FLAG-tagged WT-LKB1, K64Q or K64R, using either anti-FLAG or anti-SIRT1, 
followed by Western blotting with specific antibodies. C. PAEC were co-transfected with HA-Ub plus vectors expressing WT-LKB1, K64Q 
or K64R. After treatment with MG132 (10 μM, six hours), the nuclear and cytosol fractions were collected for Western blotting to evaluate 
the presence of LKB1 with attached polyubiquitin chains (top panel). Histone H3 and GAPDH were probed as markers for the nuclear and 
cytosol fractions, respectively. PAEC overexpressing WT-LKB1, K64Q or K64R were treated or not with cycloheximide (CHX, 50 μg/
ml), in the absence or presence of MG132 (10 μM), for six hours. The protein amounts of WT-LKB1, K64Q and K64R were quantified by 
Western blotting using anti-FLAG antibodies (bottom panel). *, P < 0.05 vs DMSO-treated samples (n = 3). D, Cells overexpressing K64Q 
were transfected with control, SIRT1 or HERC2 RNAi and subjected to subcellular fractionation to obtain the nuclear and cytosol fractions. 
The amount of K64Q was measured by Western blotting (top panel) and the results calculated as the ratio between LKB1 and GAPDH 
for cytosol fractions (data not shown), or LKB1 and histone for nuclear fractions (middle panel). *, P < 0.05 vs control RNAi (n = 3). The 
cellular distribution of K64Q was analyzed by immunofluorescence staining using anti-FLAG antibodies (bottom panel).
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Taken in conjunction, these results reveal that 
acetylation of K64 plays a pivotal role in determining the 
protein stability and function of LKB1 in endothelial cells, 
in turn modulating the proliferation of vascular smooth 
muscle cells. 
Knocking down HERC2 abolishes the vascular 
protective effects of endothelial SIRT1 in eNOS-
deficient mice
The pathophysiological significance of the above 
findings was examined in eNOS-deficient mice without 
(eNOS-/-) or with (eNOS-/-EC-SIRT1) endothelial 
overexpression of human SIRT1. The protein amount of 
SIRT1 was significantly decreased with age in carotid 
arteries of eNOS-/-, but maintained at a higher level in 
those of eNOS-/-EC-SIRT1 mice (Supplementary Figure 
9A). While HERC2 expression was not significantly 
different, LKB1 protein levels increased in carotid 
arteries of aged eNOS-/- mice. Compared to eNOS-/- mice, 
the age-induced accumulation of acetylated LKB1 was 
significantly attenuated in carotid arteries of eNOS-/-EC-
SIRT1 mice (Supplementary Figure 9B). The cellularity 
of common carotid arteries from eNOS-/-EC-SIRT1 mice 
was significantly decreased, as revealed by both manual 
Figure 6: Overexpression of K64Q causes endothelial activation and promotes vascular smooth muscle cell 
proliferation. A. SA-β-gal staining was performed in PAEC transfected with vectors encoding WT-LKB1, K64Q or K64R. Positively 
stained cells were counted manually and the results expressed as percentage of the total number of cells for comparison. B. Forty-eight 
hours after transfection, the conditioned culture media were collected for incubation with PCASMC. After 36 hours of treatment, crystal 
violet staining was performed to evaluate PCASMC proliferation. Results are presented as percentage changes compared to the WT-LKB1 
group. C. ChIP-qPCR was performed in HUVEC overexpressing WT-LKB1, K64Q or K64R using an anti-FLAG antibody to measure their 
associations with the PRR1 (-453 to -323) of human TGFβ1 promoter. D. QPCR was performed to measure the gene expressions in PAEC 
overexpressing WT-LKB1, K64Q or K64R. *, P < 0.05 vs corresponding control groups (n = 3-6).
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counting the number of nuclei and histological staining of 
α-smooth muscle actin (Figure 7A). Moreover, endothelial 
overexpression of SIRT1 prevented the age-related 
progressive deposition of collagen in carotid arteries of 
eNOS-/- mice (Figure 7A). The arterial blood pressure of 
eNOS-/-EC-SIRT1 mice was significantly lower than that 
of eNOS-/- mice from different age groups (Figure 7B).  
The structural and mechanical properties of carotid 
arteries were further evaluated by using a pressure 
myograph. The cross-sectional area and average thickness 
of the blood vessel wall (measured at a transmural 
pressure of 110 mmHg) were significantly reduced in 
preparations of eNOS-/-EC-SIRT1 compared to those of 
eNOS-/- mice (Figure 7C). With age, the elastic modulus-
stress curves in preparations of eNOS-/- mice were shifted 
significantly leftward when compared to those of eNOS-/-
EC-SIRT1 arteries (Figure 7D), indicating that endothelial 
overexpression of SIRT1 prevented age-induced vascular 
stiffness in carotid arteries of eNOS-/- mice. 
Next, control piLenti-siRNA lentivirus (Lenti-
control) or piLenti-HERC2siRNA-GFP lentivirus (Lenti-
si-HERC2; for knocking down murine HERC2) were 
administered into eNOS-/-EC-SIRT1 mice. Western 
blotting confirmed that HERC2 was significantly down-
regulated, whereas the protein levels of LKB1 and TGFβ1 
augmented in carotid arteries of eNOS-/-EC-SIRT1 mice 
after treatment with Lenti-si-HERC2 (Supplementary 
Figure 10A). As early as eight-weeks after viral treatment, 
the systolic blood pressure was significantly augmented 
by knocking down HERC2 (Figure 8A). After 24-weeks 
of viral treatment, knocking down HERC2 significantly 
increased the cellularity and collagen deposition in carotid 
arteries of eNOS-/-EC-SIRT1 mice (Figure 8B), which also 
exhibited significantly elevated expression of TGFβ1, 
MMP9, Collagen I and III (Supplementary Figure 10B). 
The cross-sectional area and blood vessel wall thickness 
were augmented significantly by knocking down HERC2 
in eNOS-/-EC-SIRT1 mice (Figure 8C). Treatment with 
Lenti-si-HERC2 increased the β-value (5.86±0.64 vs 
3.97±0.15) of the stress-strain curves in arteries of eNOS-
/-EC-SIRT1 mice, in line with the significantly leftward 
shifted elastic modulus-stress curves (Figure 8D, top 
panel). Noninvasive measurement of blood flow by echo 
ultrasonography suggested a significantly increased peak 
systolic velocity and resistive index in the right common 
carotid arteries of eNOS-/-EC-SIRT1 mice treated with 
Lenti-si-HERC2, compared to those of the Lenti-control 
groups (Figure 8D, bottom panels).  
Collectively, these results demonstrate that down-
regulation of HERC2 abolishes the beneficial effects of 
endothelial SIRT1 on the prevention of adverse arterial 
remodeling and hyperplasia in eNOS-deficient mice. 
DISCUSSION
Arterial remodeling is a physiological process that 
involves the growth, death, migration of cells, and the 
synthesis, deposition, degradation of extracellular matrix. 
Arterial stiffness due to non-compensated remodeling 
contributes to the high prevalence of hypertension and 
cardiovascular events in aged populations [1]. Effective 
control of arterial blood pressure requires a concomitant 
reduction of large artery stiffness [34]. Among the sirtuin 
family, SIRT1 is the most conserved member with 
diversified anti-ageing and vasoprotective properties [24, 
35, 36]. The present findings demonstrate that formation 
of SIRT1/HERC2/LKB1 complex in endothelial cells 
controls the process of arterial remodeling and represents a 
potential target for the development of de-stiffening drugs. 
HERC2 and LKB1 independently bind to different 
regions of SIRT1, which facilitates the formation of 
SIRT1/HERC2/LKB1 protein complexes. The amino-
terminus of SIRT1 interacts with HERC2-DOC, a ~125 
amino acid sub-region of HERC2 that is not involved in 
the binding with its other protein substrates, including 
XPA [37], BRCA1 [30], p53 [32], and RNF8 [38]. The 
binding with LKB1 does not involve the amino-terminus 
of SIRT1. However, a truncated form of SIRT1 without 
the amino-terminus cannot down-regulate LKB1. The 
stoichiometry of the SIRT1/HERC2/LKB1 complex 
explains the observations that knocking down HERC2 
does not affect the interaction between SIRT1 and LKB1, 
whereas knocking down SIRT1 abolishes that of LKB1 
with HERC2. Thus in aged arteries, although HERC2 
levels remain stable, the amount of acetylated LKB1 rises 
due to a significant reduction in SIRT1.
LKB1 in endothelial cells regulates the early stages 
of embryonic vascular remodeling. Embryonic lethality 
caused by vascular defects is a common phenotype in 
mice with whole body homozygous ablation of LKB1 [22], 
endothelium-restricted deletion of LKB1 [23], or partial 
endothelial-deletion of LKB1 [39, 40]. In matured blood 
vessels, endothelial overexpression of LKB1 inhibits 
VEGF signaling [41], enhances senescence [10, 12], 
prevents proliferation and induces apoptosis [42]. Here, 
the results suggest that in aged arteries, accumulation 
of acetylated LKB1 in the endothelium stimulates the 
proliferation of surrounding vascular smooth muscle cells 
and triggers adverse arterial remodeling. 
TGFβ1 is causally involved in post-angioplasty 
restenosis, post-infarction myocardial remodeling as well 
as other fibrotic disorders [43]. Increased TGFβ1 signaling 
is associated with elastic fiber disruption and hypertensive 
phenotypes in genetically modified mice models. Positive 
correlations exist between TGFβ1 expression and LKB1 
function [23, 44, 45]. However, detailed information 
about the molecular mechanisms underlying LKB1-
mediated TGFβ expressions is lacking. The present 
study demonstrates that acetylated LKB1 acts as a 
transcriptional activator of TGFβ1 by binding to the cis-
elements of its promoter. SIRT1 prevents the interactions 
of LKB1 with TGFβ1 promoter, by facilitating HERC2-
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Figure 7: Endothelial overexpression of SIRT1 prevents adverse arterial remodeling and alleviates hypertension in 
eNOS-deficient mice. A. The structural properties of carotid arteries collected from 16-, 32-, and 64-weeks old eNOS-/- or eNOS-/-EC-
SIRT1 mice were analyzed by H&E, α-smooth muscle actin or Masson Trichrome staining (left panels). Magnification, 100x and 400x. The 
total numbers of nuclei were counted manually in ten sections of each group of mice for comparing cellularity (right top panel). The area 
of positively stained α-smooth muscle actin (right middle panel) and the pixels of collagen deposition (right bottom panel) were quantified 
using ImageJ software for comparison. B. Arterial systolic blood pressure was recorded using the tail-cuff method (see Supporting 
Information) in mice of different ages for comparison. C. Pressure myography was performed to compare the passive geometries and 
mechanical properties of the vascular wall in carotid arteries collected from eNOS-/- and eNOS-/-EC-SIRT1 mice at different ages. Wall 
thickness and cross-sectional areas at a distending pressure of 110 mmHg were recorded for comparison. D. Young’s elastic modulus were 
calculated by fitting the circumferential stress-strain data to an exponential curve as described in Methods. The results are presented as a 
function of stress. *, P < 0.05 vs age matched eNOS-/- mice; #, P < 0.05 vs 16-weeks old eNOS-/- mice (n = 5-8).
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mediated ubiquitination and proteasomal degradation of 
acetylated LKB1 in the nuclei of endothelial cells. 
Lysine acetylation represents a key mechanism 
to regulate LKB1 protein stability and function. LKB1 
is acetylated in the liver and white adipose tissues, and 
such acetylation is enhanced by high glucose levels [46]. 
Starvation decreases LKB1 acetylation and increases its 
kinase activity to improve glucose tolerance [47]. Loss-
of-SIRT1 in senescent endothelial cells leads to the 
accumulation of LKB1 mainly in its acetylated form [12]. 
The present study has extended these previous findings 
and reveals that nuclear LKB1 is mainly in the acetylated 
form and represents a major portion highly sensitive to 
SIRT1-mediated proteasomal degradation, which may not 
involve the chemical reaction of deacetylation. Unlike 
the acetylated histone H3 peptide, incubation with SIRT1 
protein does not remove the acetyl group attached to K64 
of a synthetic LKB1 peptide (Supplementary Figure 11). 
Figure 8: Lentiviral-mediated knockdown of HERC2 abolishes the vascular protective effects of endothelial SIRT1 in 
eNOS-deficient mice. A. Arterial systolic blood pressure was recorded using a tail-cuff system in eNOS-/-EC-SIRT1 mice treated with 
Lenti-control or Lenti-si-HERC2, at eight-, 16- and 24-weeks after viral injections. B. The carotid arteries were collected from eNOS-/-EC-
SIRT1 mice after 24-weeks of treatment with Lenti-control or Lenti-si-HERC2 for analyzing the blood vessel wall cellularity and collagen 
deposition as in Figure 7A. C. Pressure myography was performed to compare the passive geometries and mechanical properties of the 
blood vessel wall in carotid arteries collected from eNOS-/-EC-SIRT1 mice after 24-weeks of treatment with either Lenti-control or Lenti-
si-HERC2. Wall thickness and cross-sectional areas were recorded as in Figure 7C for comparison. D. The β values and Young’s elastic 
modulus were calculated by fitting the circumferential stress-strain data to an exponential curve as described in Methods. The results are 
presented as a function of stress (top panel). Noninvasive measurement of velocity profiles in right common carotid arteries was performed 
using pulsed Doppler ultrasound with Vevo 2100 imaging system (see Supporting Information) (bottom panel). The peak systolic velocity 
and resistive index were recorded for comparison. *, P < 0.05 vs eNOS-/-EC-SIRT1 mice treated with Lenti-control (n = 5-6).
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The protein stabilities of other SIRT1 targets, including 
NICD [13], p53 [48, 49], NFκB [50], and FOXO1 [51], 
are also negatively correlated with their acetylation 
levels. It is possible that SIRT1 mediates the degradation 
of acetylated protein targets in a cell-specific manner by 
forming different protein complexes that contain distinct 
E3 ligases. 
The present animal studies reveal that endothelial 
overexpression of SIRT1 prevents adverse vascular 
remodeling and hypertension in eNOS-deficient mice. 
In particular, increased SIRT1 levels in the endothelium 
prevent excessive proliferation of vascular smooth muscle 
cells and deposition of collagen, thus enhancing blood 
vessel compliance and antagonizing age-induced arterial 
stiffness. Down-regulation of HERC2 abolishes the 
beneficial effects of endothelial SIRT1 overexpression 
on arterial remodeling and blood pressure control. The 
present findings support a key role of HERC2 in SIRT1-
mediated vasoprotection, by promoting the proteasomal 
degradation of acetylated LKB1 and preventing its 
accumulation in the endothelium of aged arteries.
Based on the above findings, it is proposed that the 
levels of acetylated LKB1 protein augment in endothelial 
cells under conditions such as nutritional imbalance or 
disruption of the circadian rhythm, which leads to an 
increased production of the intermediary metabolite 
acetyl-CoA [52]. Upon acetylation at K64, LKB1 exhibits 
decreased binding to STRADα but enhanced interaction 
with SIRT1. The complex formation between acetylated 
LKB1 and SIRT1/HERC2 triggers the nuclear degradation 
of the former in endothelial cells. Thus, timely formation 
of SIRT1/HERC2/LKB1 complex in endothelial cells 
allow an efficient adaptation to the dynamic changes 
of blood constituents (e.g. nutrients, metabolites and 
oxidative radicals). In senescent endothelial cells or aged 
arteries, loss-of-SIRT1 expression or function results in 
an increased nuclear accumulation of acetylated LKB1, 
leading to irreversible structural alterations of the blood 
vessel wall, adverse arterial remodeling and vascular 
stiffness. 
MATERIALS AND METHODS
Animals
All animal care and experimental procedures 
(details in online Supplementary file) were approved by 
the Committee on the Use of Live Animals for Teaching 
and Research of the University of Hong Kong, and carried 
out in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the US National 
Institutes of Health (Eighth Edition, National Research 
Council, USA, 2011). 
RNA interference
Three sets of small interfering 
RNAs (RNAi) targeting human HERC2 
(GCAACACAGTCGTGAAAGA; 
GCGGAAGCCTCATTAGAAA; 
and GAGCTGATTTCTTGAGTAA) or porcine 
HERC2 (GGACTTTCTGTGTCAAATA; 
CATTAAGACACATCAAGAA and 
GGAGGATTGCTCAGAAGAT) and two sets 
of RNAi (GGCACAGATCCTCGAACAA and 
CCAGTAGCACTAATTCCAA) targeting the conserved 
sequences of human and porcine SIRT1 were purchased 
from RiboBio (Guangzhou, China). The mixture 
containing 50 nM RNAi was used for transfection using 
Lipofectamine 2000 (Life Technologies, Grand Island, 
NY, USA). 
Four sets of piLenti-siRNA-GFP lentiviral vectors 
targeting murine HERC2 were obtained from Applied 
Biological Materials Inc and tested in 3T3-L1 cell 
cultures (data not shown). The most effective siRNA 
(ACAGAGACTGTTACCTATTAAACCCTGCC) was 
packaged to produce the recombinant lentivirus (piLenti-
HERC2siRNA-GFP) with a titer of 1.6 × 108 IU/ml for 
subsequent administration to mice.
Plasmids and site-directed mutagenesis
The mammalian expression vectors hSIRT1-
3FLAG, pcDNA-SIRT1 and ∆SIRT1-FLAG were used for 
overexpressing full-length human SIRT1 with a carboxy-
terminal triple-FLAG tag [10], full-length human SIRT1 
without any fusion tags [26], and a truncated FLAG-
tagged human SIRT1 lacking 105 amino acids at the 
amino-terminus, respectively.
Primers (Supplementary Table 1) were designed 
by referring to the cDNA sequence of human HERC2 
(NM_004667.5) for cloning three gene fragments 
into the pCMV-3Tag-3 mammalian expression vector 
(Agilent Technologies, La Jolla, CA, USA). DNA 
sequencing confirmed that the three vectors, including 
DOC-3FLAG, RCC2-3FLAG, and HECT-3FLAG, encode 
the sub-domains of HERC2 from amino acid 2765 to 
2910 (HERC2-DOC), 2786 to 3642 (HERC2-RCC2) and 
4419 to 4834 (HERC2-HECT), respectively, all of which 
contain a carboxy-terminal triple-FLAG tag. In addition, 
an expression vector (HECT-noTag) encoding the HERC2-
HECT domain without any fusion tags was constructed.
The cDNA of murine LKB1 (NM_011492.4) 
was sub-cloned into the pCMV-3Tag-3 vector 
using forward (5’-TGGTACCGAGCTCGG 
ATCCACTAGTCCAGTGT-3’) and reverse 
(5’-ATATTTCTCGAGTCGCTGCTGCTTGCA-3’) 
primers to construct a mammalian expression vector 
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(LKB1-WT-3FLAG) encoding full-length LKB1 with 
a carboxy-terminal triple-FLAG tag. Site-directed 
mutagenesis was performed using LKB1-WT-3FLAG as 
the template to obtain vectors encoding LKB1 mutants 
with the lysine (K) 64 residue replaced by either arginine 
(R) (LKB1-K64R-3FLAG) or glutamine (Q) (LKB1-
K64Q-3FLAG). All mutations were confirmed by DNA 
sequencing. 
The prokaryotic vectors for expressing the amino-
terminus (HERC2-NH2, residues 1–199) and CPH 
domain (HERC2-CPH, residues 2547–2640) of human 
HERC2 as fusion proteins with glutathione S-transferase 
were kindly provided by Dr José Luis Rosa [32]. The 
prokaryotic vectors expressing polyhistidine (His)-tagged 
human SIRT1 (pPROEX-HTb-SIRT1) or murine LKB1 
(pPROEX-HTb-LKB1) were constructed by sub-cloning 
the cDNAs (from hSIRT1-3FLAG and LKB1-WT-
3FLAG, respectively) into a pPROEX-HTb vector (Life 
Technologies).
In vitro ubiquitination assay
HERC2 protein was immunoprecipitated from 
MDA-MB-231 cell lysates for assaying ubiquitination 
in vitro. In brief, 100 ng ubiquitin-activating enzyme 
(E1), 200 ng ubiquitin-conjugating enzyme (E2), one μg 
FLAG-tagged ubiquitin, and two μg purified His-tagged 
LKB1 or SIRT1 protein as substrates were included 
in an assay buffer containing 25 mM HEPES (pH 7.4), 
10 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 0.5 mM 
dithiothreitol and 3 mM ATP. The reaction was performed 
at 37°C for one hour. Ubiquitinated-LKB1 or SIRT1 was 
detected by Western blotting using anti-LKB1 or anti-
SIRT1antibodies, respectively. 
Microscopic morphometry and vessel wall 
cellularity 
The common carotid artery was carefully removed, 
fixed in neutral buffered formaldehyde, dehydrated and 
embedded in paraffin. The tissue blocks were cut into 
sections of five μm thickness for hematoxylin and eosin 
(H&E) staining, immunohistochemistry or the evaluation 
of collagen deposition using a Trichrome Stain (Masson) 
Kit (Sigma, Saint Louis, MO, USA). The intimal (area 
between the lumen and the internal elastic lamina), medial 
(area between the internal and the external elastic lamina), 
and total blood vessel wall area were determined by 
computerized digital planimetry, using a video microscope 
(Olympus BX41) with DP2-BSW imaging software. 
The total number of nuclei in the different blood vessel 
layers was counted manually to determine the cellularity 
of the arterial wall. The pixel intensity of brown/blue 
staining in blood vessel sections was quantified using 
ImageJ software (National Institutes of Health, USA) to 
evaluate the amount of α-smooth muscle actin or collagen 
deposition, respectively.
Structural and mechanical properties of carotid 
arteries
Mouse left common carotid arteries (10 mm 
segments upstream of the bifurcation) were mounted into 
a Pressure Myograph system (DMT-100P, DMT, Aarhus, 
Denmark) for the assessment of mechanical properties 
under passive conditions [53]. The blood vessels were 
equilibrated in calcium-free Krebs buffer solution (4.69 
mM KCl, 118.99 mM NaCl, 25 mM NaHCO
3
, 5.5 mM 
glucose, 1.17 mM MgSO4, 1.18 mM KH2PO4 and 3 
mM EDTA) kept at 37 °C and aerated with 95% O2 and 
5% CO2. Each segment was primed by increasing the 
transmural pressure stepwise (10 mmHg every three 
minutes) from 10 to 190 mmHg. After equilibrating at 
10 mmHg for 30 minutes, transmural pressure was raised 
stepwise (10 mmHg increments every three minutes) 
to 150 mmHg. During this procedure the changes of 
the internal and external diameter were measured at 
three different locations along the arterial segment. The 
cross-sectional area of the arterial wall, average wall 
thickness and wall-to-lumen ratio were calculated using 
the Ion Wizard (Version 6.0, Ion Optix Corp., Milton, 
Massachusetts, USA) [54]. Comparisons are based on the 
calculations of the following parameters: 
Wall cross-sectional area (CSA)
, where De is the external 
diameter and Di is the internal diameter of the vessel for a 
given transmural pressure.
Circumferential strain
, where Dio represents the internal 
diameter at a pressure of 10 mmHg. 
Circumferential stress
, where P is a given transmural pressure 
(1 mmHg = 0.133 kPa). 
Elastic modulus
The incremental elastic modulus (Einc or Young’s 
modulus) describes the intrinsic elastic properties of the 
wall material, independently of blood vessel geometry. 
It was obtained by fitting the stress-strain data to the 
exponential curve σ = σo e
βε, where σo is the stress at a 
pressure of 10 mmHg and β is a constant related to the 
tangent of the stress-strain curve, i.e. β is proportional to 
the incremental elastic modulus. 
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Data calculation and statistical analysis
All calculations were performed using SPSS 19.0 
software (IBM Corporation, NY, USA). All experiments 
were repeated at least three times. Results are presented 
as means ± SEM. Statistical analysis of differences was 
performed using Student’s t-test for unpaired observations 
or one-way ANOVA with Bonferroni correction for 
multiple comparisons. P values less than 0.05 were 
considered to indicate statistically significant differences. 
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Translational perspective
Arterial remodeling not only is a physiological 
process during the formation of blood vessels, but 
also plays an important role in the development 
of cardiovascular diseases including restenosis, 
hypertension and atherosclerosis. Endothelial disruption 
and dysfunction facilitate adverse arterial remodeling 
and alter the mechanical responses of the blood vessel 
wall. The present study identifies endothelial SIRT1 as 
a key modulator of arterial remodeling and uncovers an 
important molecular signaling axis for pathophysiological 
remodeling of the arterial wall. The results support 
the potential of early interventions in endothelial cells 
to prevent ageing-induced vascular damage and the 
development of arterial occlusive diseases.
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